Privia Health (PRVA)
Market Price (12/27/2025): $24.13 | Market Cap: $3.0 BilSector: Health Care | Industry: Health Care Services
Privia Health (PRVA)
Market Price (12/27/2025): $24.13Market Cap: $3.0 BilSector: Health CareIndustry: Health Care Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -15% | Weak multi-year price returns2Y Excs Rtn is -43%, 3Y Excs Rtn is -78% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 105x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 27x, P/EPrice/Earnings or Price/(Net Income) is 163x |
| Low stock price volatilityVol 12M is 31% | Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -3.5% | |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine. Themes include Telehealth Platforms, Remote Patient Monitoring, and Health Data Analytics. | Key risksPRVA key risks include [1] its operational reliance on key third-party vendors, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -15% |
| Low stock price volatilityVol 12M is 31% |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine. Themes include Telehealth Platforms, Remote Patient Monitoring, and Health Data Analytics. |
| Weak multi-year price returns2Y Excs Rtn is -43%, 3Y Excs Rtn is -78% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 105x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 27x, P/EPrice/Earnings or Price/(Net Income) is 163x |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -3.5% |
| Key risksPRVA key risks include [1] its operational reliance on key third-party vendors, Show more. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
The 4.7% movement in Privia Health (PRVA) stock from August 31, 2025, to December 27, 2025, can be attributed to several key factors:
<b>1. Strong Third Quarter 2025 Financial Performance.</b><br><br>
Privia Health reported robust financial results for the third quarter of 2025, significantly exceeding Wall Street's expectations. The company's revenue increased by 32.5% year-over-year to $580.4 million, and adjusted EPS of $0.29 surpassed analyst estimates by 33.7%. Adjusted EBITDA also beat estimates by 35%, reaching $38.19 million.
<b>2. Raised Full-Year 2025 Guidance.</b><br><br>
Following its strong Q3 performance, Privia Health raised its full-year 2025 guidance for key operating and financial metrics, including revenue and adjusted EBITDA. This upward revision signaled management's confidence in the company's continued growth trajectory and operational efficiency.
<b>3. Strategic Acquisition of Evolent Health's ACO Business.</b><br><br>
In September 2025, Privia Health announced the acquisition of an Accountable Care Organization (ACO) business from Evolent Health for $100 million. This strategic move is expected to add over 120,000 value-based care attributed lives and is projected to positively contribute to adjusted EBITDA in 2026, expanding Privia Health's value-based care footprint.
<b>4. Exceptional Medicare Shared Savings Program (MSSP) Results.</b><br><br>
Privia Health's ACOs delivered impressive results in the 2024 performance year of the Medicare Shared Savings Program, generating over $233 million in total savings, representing a 32% year-over-year increase. This strong performance in value-based care arrangements also led to an increase in the company's adjusted EBITDA guidance for the full year 2025.
<b>5. Positive Analyst Sentiment and Upgraded Price Targets.</b><br><br>
Throughout the period, many analysts maintained or upgraded their ratings for Privia Health, with a consensus of "Moderate Buy" and an average 1-year price target of $30.42 as of December 24, 2025. Several firms reiterated "Buy" or "Overweight" ratings and increased their price targets in November and December 2025, reflecting optimism about the company's financial performance and strategic initiatives.
Show moreStock Movement Drivers
Fundamental Drivers
The 0.7% change in PRVA stock from 9/26/2025 to 12/26/2025 was primarily driven by a 13.9% change in the company's Net Income Margin (%).| 9262025 | 12262025 | Change | |
|---|---|---|---|
| Stock Price ($) | 23.96 | 24.13 | 0.71% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 1900.07 | 2042.57 | 7.50% |
| Net Income Margin (%) | 0.78% | 0.89% | 13.87% |
| P/E Multiple | 197.18 | 163.07 | -17.30% |
| Shares Outstanding (Mil) | 122.13 | 122.77 | -0.52% |
| Cumulative Contribution | 0.71% |
Market Drivers
9/26/2025 to 12/26/2025| Return | Correlation | |
|---|---|---|
| PRVA | 0.7% | |
| Market (SPY) | 4.3% | 36.5% |
| Sector (XLV) | 15.2% | 44.0% |
Fundamental Drivers
The 9.7% change in PRVA stock from 6/27/2025 to 12/26/2025 was primarily driven by a 13.4% change in the company's Total Revenues ($ Mil).| 6272025 | 12262025 | Change | |
|---|---|---|---|
| Stock Price ($) | 22.00 | 24.13 | 9.68% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 1801.24 | 2042.57 | 13.40% |
| Net Income Margin (%) | 0.87% | 0.89% | 2.56% |
| P/E Multiple | 169.88 | 163.07 | -4.01% |
| Shares Outstanding (Mil) | 120.62 | 122.77 | -1.78% |
| Cumulative Contribution | 9.65% |
Market Drivers
6/27/2025 to 12/26/2025| Return | Correlation | |
|---|---|---|
| PRVA | 9.7% | |
| Market (SPY) | 12.6% | 35.7% |
| Sector (XLV) | 17.0% | 39.9% |
Fundamental Drivers
The 19.7% change in PRVA stock from 12/26/2024 to 12/26/2025 was primarily driven by a 19.0% change in the company's Net Income Margin (%).| 12262024 | 12262025 | Change | |
|---|---|---|---|
| Stock Price ($) | 20.16 | 24.13 | 19.69% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 1716.32 | 2042.57 | 19.01% |
| Net Income Margin (%) | 0.75% | 0.89% | 19.04% |
| P/E Multiple | 188.11 | 163.07 | -13.31% |
| Shares Outstanding (Mil) | 119.66 | 122.77 | -2.60% |
| Cumulative Contribution | 19.61% |
Market Drivers
12/26/2024 to 12/26/2025| Return | Correlation | |
|---|---|---|
| PRVA | 19.7% | |
| Market (SPY) | 15.8% | 33.9% |
| Sector (XLV) | 13.3% | 36.5% |
Fundamental Drivers
The 4.1% change in PRVA stock from 12/27/2022 to 12/26/2025 was primarily driven by a 61.1% change in the company's Total Revenues ($ Mil).| 12272022 | 12262025 | Change | |
|---|---|---|---|
| Stock Price ($) | 23.18 | 24.13 | 4.10% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 1267.57 | 2042.57 | 61.14% |
| P/S Multiple | 2.04 | 1.45 | -28.93% |
| Shares Outstanding (Mil) | 111.59 | 122.77 | -10.02% |
| Cumulative Contribution | 3.05% |
Market Drivers
12/27/2023 to 12/26/2025| Return | Correlation | |
|---|---|---|
| PRVA | -0.4% | |
| Market (SPY) | 48.0% | 31.3% |
| Sector (XLV) | 18.2% | 29.2% |
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| PRVA Return | - | -26% | -12% | 1% | -15% | 21% | -32% |
| Peers Return | 16% | 38% | -12% | 21% | 26% | 16% | 150% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 18% | 114% |
Monthly Win Rates [3] | |||||||
| PRVA Win Rate | - | 44% | 50% | 50% | 42% | 58% | |
| Peers Win Rate | 52% | 65% | 42% | 68% | 57% | 52% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | |
Max Drawdowns [4] | |||||||
| PRVA Max Drawdown | - | -39% | -28% | -10% | -30% | -4% | |
| Peers Max Drawdown | -34% | -5% | -26% | -7% | -9% | -23% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: HPQ, HPE, IBM, CSCO, AAPL.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/26/2025 (YTD)
How Low Can It Go
| Event | PRVA | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -61.9% | -25.4% |
| % Gain to Breakeven | 162.8% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
Compare to HPQ, HPE, IBM, CSCO, AAPL
In The Past
Privia Health's stock fell -61.9% during the 2022 Inflation Shock from a high on 6/28/2021. A -61.9% loss requires a 162.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
AI Analysis | Feedback
Here are 1-3 brief analogies for Privia Health (PRVA):
- Shopify for doctor's offices: Just as Shopify provides a comprehensive platform and tools for small businesses to run their e-commerce stores, Privia Health offers a full suite of technology and services (EHR, revenue cycle management, managed care contracting) to help independent physician groups run their practices more efficiently and profitably.
- Salesforce for medical practices: Similar to how Salesforce provides cloud-based solutions to manage customer relationships and streamline business operations for various industries, Privia Health delivers an integrated platform and services designed to optimize clinical workflows, financial performance, and patient engagement for healthcare providers.
AI Analysis | Feedback
- Physician Enablement & Practice Management Services: Privia Health provides comprehensive administrative, operational, and financial support to physician groups, helping them manage their practices efficiently.
- Value-Based Care Solutions: The company enables healthcare providers to transition to and succeed in value-based care models through population health management, care coordination, and risk management programs.
- Integrated Technology & Data Analytics: Privia Health offers a suite of technology solutions, including electronic health record optimization, patient engagement platforms, and data analytics to enhance clinical and financial performance.
AI Analysis | Feedback
Privia Health (PRVA) Major Customers
Privia Health (PRVA) sells primarily to other companies. Its business model involves partnering with and enabling independent physician groups and entering into value-based care arrangements with various health plans.
According to Privia Health's financial filings (e.g., 2023 10-K), no individual payor (health plan) accounted for more than 10% of its total revenues, indicating a diversified customer base and the absence of a single "major customer" by revenue concentration. Similarly, their network consists of numerous independent physician groups, none of which individually represent a dominant portion of their revenue.
Therefore, while specific "major customer companies" cannot be named due to revenue diversification, Privia Health's customers broadly fall into two categories of companies:
- Independent Physician Groups and Practices: These are the medical groups, individual physicians, and clinical practices that join the Privia network to leverage its technology, practice management services, and value-based care contracting capabilities. These are typically local or regional entities rather than large public companies.
- Health Plans and Payors: Privia Health partners with various national and regional health insurance companies and managed care organizations to implement value-based care programs. These partnerships are crucial for shared savings and quality incentives. Examples of major health plans that Privia Health typically works with across its markets include those owned by, but not limited to:
- UnitedHealth Group (NYSE: UNH)
- Elevance Health (NYSE: ELV)
- CVS Health (which owns Aetna) (NYSE: CVS)
- Humana (NYSE: HUM)
- Cigna Group (NYSE: CI)
- Centene Corporation (NYSE: CNC)
It is important to note that while Privia Health collaborates with these types of major health plans, none individually constitute a "major customer" by revenue concentration based on Privia's public disclosures.
AI Analysis | Feedback
nullAI Analysis | Feedback
Parth Mehrotra, Chief Executive Officer
Parth Mehrotra became the Chief Executive Officer of Privia Health after serving as President and Chief Operating Officer for over seven years. In his current role, he oversees company efforts related to growth, financial and operational efficiency across all markets, shared corporate functions, and Privia's business development efforts. He is also responsible for setting corporate strategy and leading Privia's technology innovation. Prior to joining Privia, he served as Chief Operating Officer of Brighton Health Group, which was Privia Health's former parent company. Before that, Mr. Mehrotra was a Senior Financial Officer at athenahealth and a member of the Healthcare Investment Banking group at Goldman Sachs for seven years, where he was involved in the athenahealth IPO.
David Mountcastle, Executive Vice President & Chief Financial Officer
David Mountcastle has extensive experience in both the healthcare and technology industries, working with companies ranging from startups to large, publicly traded enterprises. Before joining Privia Health, he was the Chief Financial Officer for Brainware, Inc., which he helped grow from a startup to its acquisition by Lexmark International for more than $150 million. Prior to that, Mr. Mountcastle was the Controller/Director of Finance for VT iDirect Technologies, where he helped guide the company from a startup to a strategic exit for its investors. Earlier in his career, he served as the Controller for HealthSpring Inc., which was later sold to United HealthCare, and also as the CFO for Southern Health.
Shawn Morris, Board Member (former CEO)
Shawn Morris previously served as the Chief Executive Officer of Privia Health from 2018 to 2023 and is currently a member of its board of directors. During his tenure as CEO, Privia Health completed its initial public offering in 2021. Prior to joining Privia Health, Mr. Morris was the President and Chief Operating Officer of Cigna-HealthSpring, a Cigna company, from 2016 to 2018. From 2010 to 2016, he held various leadership roles at Cigna-HealthSpring, including Chief Operating Officer, President of Development & Innovation, and Executive Vice President, overseeing the financial and operational performance of Cigna's Medicare Advantage business. Before his time at HealthSpring, Mr. Morris held leadership positions managing physician-led IPAs and a multi-specialty medical group, and began his career as a public accountant working with physician practices.
David Rothenberg, Co-Founder
David Rothenberg is a co-founder of Privia Health and has been a healthcare entrepreneur for over 20 years. He served as President of Privia for more than eight years, leading sales, marketing, and growth initiatives for the company. Mr. Rothenberg also co-founded MDLinx, a physician portal and doctor-focused market research company that was subsequently acquired by a division of Sony.
Chris Voigt, Executive Vice President & Chief Technology Officer
Chris Voigt serves as the Executive Vice President and Chief Technology Officer of Privia Health, bringing over 14 years of experience in healthcare interoperability. Before his role at Privia, he led corporate development for MobileMD, a health information exchange service provider that was acquired by Siemens in 2011. He also previously headed the U.S. HIE practice for systems integrator CGI.
AI Analysis | Feedback
The key risks to Privia Health (PRVA) include navigating the complex regulatory landscape, operational reliance on third-party technology vendors, and pressures related to reimbursement rates and payer contracts.
- Regulatory, Compliance, and Data Security Risks: Privia Health operates within a heavily regulated healthcare environment, making it susceptible to complex and evolving federal and state laws and regulations, including those related to privacy and security such as HIPAA. Maintaining robust compliance programs and adapting to changing legal interpretations are critical operational risks. The company also faces inherent cybersecurity and privacy risks concerning protected health information, including potential security threats, incidents, or data breaches.
- Reliance on Key Vendors and Technology Execution Risks: A significant operational risk for Privia Health is its reliance on key third-party vendors, most notably athenahealth, Inc., which serves as its primary electronic medical record vendor. Furthermore, the company faces execution risks related to its growth strategy and the timely implementation of its proprietary cloud-based technology solutions for its physicians and new medical groups.
- Reimbursement and Payer Contract Risks: Privia Health is exposed to potential decreases in reimbursement rates from both governmental and private payers. Changes to payment terms, as well as challenges in negotiating and retaining favorable contracts with private third-party payers, could significantly impact the company's financial performance and long-term profitability.
AI Analysis | Feedback
The accelerated trend of large healthcare organizations (payers, pharmacy chains, and tech giants such as CVS/Aetna, Amazon, and UnitedHealth Group's Optum) acquiring or building out extensive primary care and specialty provider networks. These entities are creating highly integrated healthcare ecosystems, often combining insurance, pharmacy, and direct provider services with advanced digital health platforms. This development creates direct competition to independent physician practices—Privia Health's core partners—on a significant scale, leveraging greater capital, integrated data, and streamlined patient pathways. Examples like CVS's acquisition of Oak Street Health and Amazon's acquisition of One Medical underscore this strategic shift, which actively diminishes the market for independent practices and challenges the value proposition of companies that enable physicians to remain independent within a fragmented system.
AI Analysis | Feedback
Privia Health (PRVA) operates in the U.S. healthcare market, primarily offering physician enablement and value-based care solutions. The addressable markets for these main product and service categories are substantial within the United States.
-
Physician Enablement Services: The U.S. physician enablement services market is estimated to be between $20 billion and $40 billion. A segment within this, the practice management system market, is projected to grow from $6.02 billion in 2024 to $10.1 billion by 2030 in the U.S. More broadly, the physician practice management market in North America, which holds a major revenue share, was estimated at US$118.9 billion in 2023 and is projected to reach US$291.7 billion by 2034, growing at a compound annual growth rate (CAGR) of 8.5% from 2024 to 2034.
-
Value-Based Healthcare Services: The U.S. value-based healthcare service market size was valued at approximately USD 4.01 trillion in 2024 and is expected to grow at a CAGR of 7.4% from 2025 to 2030. Other estimates place the U.S. value-based healthcare service market size at USD 3.6 trillion in 2023, with an anticipated CAGR of 6.2% from 2024 to 2032. The market is projected to reach roughly USD 6.92 trillion by 2034, with a CAGR of 6.66% from 2025 to 2034. A significant component of this, the accountable care organization (ACO) segment, held a revenue of approximately USD 1.3 trillion in the U.S. in 2023.
AI Analysis | Feedback
Privia Health (NASDAQ: PRVA) is expected to drive future revenue growth over the next 2-3 years through several key strategies:
- Growth in Implemented Providers: Privia Health continues to expand its network by adding new healthcare providers. In Q3 2025, the company reported a 13.1% year-over-year increase in implemented providers, reaching 5,250. This growth is a consistent driver of platform revenue and is projected to increase by approximately 11.2% year-over-year to 5,325 by the end of 2025.
- Expansion of Value-Based Care (VBC) Attributed Lives: The company is significantly increasing its participation and success in value-based care models. Privia Health expanded its value-based attributed lives to 1,406,000 in Q3 2025, a 12.8% increase, driven by strong performance in programs like the Medicare Shared Savings Program (MSSP) and other VBC arrangements. The company anticipates attributed lives growth of approximately 12.5% in 2025.
- Strategic Acquisitions: Privia Health is leveraging acquisitions to accelerate growth, notably with the definitive agreement to acquire an Accountable Care Organization (ACO) business from Evolent Health. This acquisition, expected to close in Q4 2025 for $100 million in cash plus an earn-out, is projected to add over 120,000 value-based care attributed lives, expanding Privia's total VBC attributed lives to over 1.5 million and contributing positively to adjusted EBITDA in 2026.
- Entry into New Geographic Markets: Geographic expansion is a critical component of Privia's growth strategy. The company currently operates in 15 states and the District of Columbia. New market entries, such as Arizona, have contributed to increased practice collections, and management views entering new markets as key to expanding its national footprint.
- Same-Store Growth and Increased Utilization: Beyond adding new providers and markets, Privia Health is experiencing growth within its existing practices. The company has reported continued strength in "same-store growth" and higher utilization trends, indicating that existing patient panels and services are generating increased revenue. This reflects momentum across the business and contributes to overall revenue growth and margin expansion.
AI Analysis | Feedback
Share Repurchases
- Privia Health has not reported significant share repurchase programs or authorizations over the last 3-5 years. The 3-year average share buyback ratio indicates a net issuance of shares.
Share Issuance
- Privia Health went public in May 2021 through an Initial Public Offering (IPO), offering 22.4 million shares at $23 per share, aiming to raise approximately $516 million. The gross proceeds to Privia Health from this offering were expected to be about $64.4 million.
- As of October 31, 2025, the company had 123,001,529 shares of common stock outstanding.
- The company has issued common stock through the exercise of stock options and the vesting of restricted stock units.
Outbound Investments
- In September 2025, Privia Health signed an agreement to acquire an Accountable Care Organization (ACO) business from Evolent Health, Inc. for $100 million in cash, with a potential earn-out of up to $13 million. This acquisition is expected to close in the fourth quarter of 2025 and aims to add over 120,000 value-based care attributed lives.
- In the second quarter of 2025, Privia Health deployed $95 million for an IMS transaction in Arizona, which involved adding $64.4 million of payer/physician network intangibles and $30.6 million of goodwill.
Capital Expenditures
- Privia Health anticipates "de minimis capital expenditures" for the full-year 2025.
- At the time of its IPO in 2021, the company stated that a portion of the net proceeds would be used for capital expenditures, in addition to other general corporate purposes such as working capital, research and development, and business development.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to PRVA. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 21.4% | 21.4% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -7.4% | -7.4% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 18.0% | 18.0% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.9% | 3.9% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 12.2% | 12.2% | -5.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Privia Health
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 51.32 |
| Mkt Cap | 158.8 |
| Rev LTM | 56,496 |
| Op Inc LTM | 7,584 |
| FCF LTM | 7,327 |
| FCF 3Y Avg | 7,366 |
| CFO LTM | 8,590 |
| CFO 3Y Avg | 8,697 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 7.4% |
| Rev Chg 3Y Avg | 3.2% |
| Rev Chg Q | 9.4% |
| QoQ Delta Rev Chg LTM | 2.1% |
| Op Mgn LTM | 12.1% |
| Op Mgn 3Y Avg | 11.9% |
| QoQ Delta Op Mgn LTM | 0.2% |
| CFO/Rev LTM | 14.6% |
| CFO/Rev 3Y Avg | 17.1% |
| FCF/Rev LTM | 11.8% |
| FCF/Rev 3Y Avg | 12.1% |
Segment Financials
Revenue by Segment| $ Mil | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Care for its patients’ needs | 1,658 | |||
| Capitated revenue | 218 | |||
| Care management fees (per member per month (PMPM)) | 36 | 37 | 27 | |
| Fee-for-service (FFS)-administrative services | 95 | 69 | 58 | |
| Fee-for-service (FFS)-patient care | 869 | 772 | 647 | |
| Other revenue | 6 | 5 | 18 | |
| Shared savings | 133 | 83 | 66 | |
| Total | 1,658 | 1,357 | 966 | 817 |
Price Behavior
| Market Price | $24.13 | |
| Market Cap ($ Bil) | 3.0 | |
| First Trading Date | 04/29/2021 | |
| Distance from 52W High | -8.6% | |
| 50 Days | 200 Days | |
| DMA Price | $24.35 | $23.01 |
| DMA Trend | indeterminate | indeterminate |
| Distance from DMA | -0.9% | 4.8% |
| 3M | 1YR | |
| Volatility | 28.2% | 31.6% |
| Downside Capture | 109.79 | 66.29 |
| Upside Capture | 90.94 | 74.37 |
| Correlation (SPY) | 37.7% | 34.0% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.05 | 0.85 | 0.78 | 1.05 | 0.55 | 0.87 |
| Up Beta | 1.09 | 1.05 | 1.05 | 1.58 | 0.62 | 0.80 |
| Down Beta | -0.04 | 0.33 | 0.49 | 0.46 | 0.15 | 0.31 |
| Up Capture | 109% | 81% | 84% | 97% | 69% | 121% |
| Bmk +ve Days | 13 | 26 | 39 | 74 | 142 | 427 |
| Stock +ve Days | 7 | 17 | 28 | 58 | 123 | 366 |
| Down Capture | 123% | 114% | 82% | 123% | 83% | 106% |
| Bmk -ve Days | 7 | 16 | 24 | 52 | 107 | 323 |
| Stock -ve Days | 13 | 24 | 34 | 65 | 122 | 376 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
nullBased On 5-Year Data
nullBased On 10-Year Data
nullReturns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/6/2025 | -4.2% | -3.2% | -5.6% |
| 8/7/2025 | -1.4% | 6.3% | 17.7% |
| 5/8/2025 | 7.5% | 4.2% | -0.6% |
| 2/27/2025 | 5.8% | 6.8% | -4.7% |
| 11/7/2024 | 6.5% | 3.2% | 0.1% |
| 8/8/2024 | 5.9% | 5.5% | 2.1% |
| 5/9/2024 | -4.4% | -7.9% | -9.1% |
| 2/27/2024 | 9.7% | 9.4% | -5.2% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 10 | 10 | 8 |
| # Negative | 7 | 7 | 9 |
| Median Positive | 7.0% | 6.3% | 6.5% |
| Median Negative | -4.2% | -3.2% | -5.6% |
| Max Positive | 14.3% | 18.3% | 44.2% |
| Max Negative | -4.8% | -14.8% | -20.3% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 9302025 | 11062025 | 10-Q 9/30/2025 |
| 6302025 | 8072025 | 10-Q 6/30/2025 |
| 3312025 | 5082025 | 10-Q 3/31/2025 |
| 12312024 | 2272025 | 10-K 12/31/2024 |
| 9302024 | 11072024 | 10-Q 9/30/2024 |
| 6302024 | 8082024 | 10-Q 6/30/2024 |
| 3312024 | 5092024 | 10-Q 3/31/2024 |
| 12312023 | 2272024 | 10-K 12/31/2023 |
| 9302023 | 11032023 | 10-Q 9/30/2023 |
| 6302023 | 8032023 | 10-Q 6/30/2023 |
| 3312023 | 5042023 | 10-Q 3/31/2023 |
| 12312022 | 3012023 | 10-K 12/31/2022 |
| 9302022 | 11102022 | 10-Q 9/30/2022 |
| 6302022 | 8112022 | 10-Q 6/30/2022 |
| 3312022 | 5122022 | 10-Q 3/31/2022 |
| 12312021 | 3252022 | 10-K 12/31/2021 |
Insider Activity
Expand for More| Owner | Title | Filing Date | Action | Price | Shares | TransactedValue | Value ofHeld Shares | Form | |
|---|---|---|---|---|---|---|---|---|---|
| 0 | Mehrotra Parth | Chief Executive Officer | 5142025 | Sell | 24.99 | 13,773 | 344,187 | 10,574,344 | Form |
| 1 | Mountcastle David | EVP & Chief Financial Officer | 5142025 | Sell | 24.99 | 3,322 | 83,017 | 4,320,996 | Form |
| 2 | Mountcastle David | EVP & Chief Financial Officer | 5022025 | Sell | 23.33 | 3,445 | 80,372 | 4,111,469 | Form |
| 3 | Morris Matthew Shawn | 5022025 | Sell | 23.33 | 10,309 | 240,509 | 1,394,947 | Form | |
| 4 | Mehrotra Parth | Chief Executive Officer | 5022025 | Sell | 23.33 | 15,100 | 352,283 | 10,598,376 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.